Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance) Meeting Abstract
| Authors: | Magbanua, M. J. M.; Savenkov, O. O.; Asmus, E.; Ballman, K. V.; Scott, J. H.; Park, J.; Dickler, M. N.; Partridge, A. H.; Carey, L. A.; Winer, E. P.; Rugo, H. S. |
| Abstract Title: | Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 46s |
| Language: | English |
| ACCESSION: | WOS:000487345804007 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.1049 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1049 -- Source: Wos |
